BioPorto announces the Annual Report for 2025

About this update from Bioporto A/s

[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v1ZhoICY2NNyMa6IbavSEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"March 26, 2026Announcement no. 04","length":34,"tagName":"p"},{"type":"text","content":" ","length":1,"tagName":"p"},{"type":"text","content":"BioPorto announces the Annual Report for 2025","length":45,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark, March 26, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or company) (CPH:BIOPOR), today announced the annual financial results for 2025. The financial results for 2025 confirm the preliminary unaudited 2025 financial figures released February 5, 2026.","length":291,"tagName":"p"},{"type":"text","content":"Financial highlights for FY 2025                                                                                                                            ","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenues amounted to DKK 40.3 million – an 11% growth compared to 2024 and 13% growth at constant exchange rates (CER), and within the latest guidance of DKK 40-45 million.","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"Total NGAL revenues increased to DKK 28.2m by 22% and 25% at CER. The growth was primarily driven by an increase in NGAL revenues in the US from Research Use Only (RUO) of 25% ...

More updates from Bioporto A/s